Bernie Sanders to block all Biden health nominees until admin delivers plan to lower drug prices: Report

Biden nominated Monica Bertagnolli to lead the National Institutes of Health last month

Progressive Sen. Bernie Sanders, I-Vt., says he will oppose President Biden's nominee to lead the National Institutes of Health (NIH), and any other health nominations, until the administration delivers its plan to lower drug prices, according to a report by The Washington Post.

"I will oppose all nominations until we have a very clear strategy on the part of the government … as to how we’re going to lower the outrageously high cost of prescription drugs," Sanders, who chairs the Senate Committee on Health Education, Labor and Pensions (HELP) told The Post in an interview.

Sanders' decision puts the confirmation of Biden NIH nominee Monica Bertagnolli in doubt, at least for the near future, considering that in his position as the chair of the HELP Committee, he determines when reviews of relevant nominees take place. This means the Biden administration will not be able to get any health agency nominees confirmed if he holds true to his promise.


Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders (I-VT)

Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders (I-VT) delivers opening remarks during the confirmation hearing for Deputy Labor Secretary Julie Su to be the next secretary of the Labor Department in the Dirksen Senate Office Building on Capitol Hill on April 20, 2023 in Washington, DC. (Chip Somodevilla/Getty Images)

When reached for comment, a senior administration official told Fox News Digital, "The President shares the Senator’s concerns on drug pricing. That’s why he signed into law the Inflation Reduction Act, the most consequential law addressing the high cost of prescription drugs."

"As a result, insulin is now capped at $35 a month for seniors on Medicare. And for the first time ever – instead of just paying whatever drug companies want to charge – Medicare will be able to drive prices down by negotiating with companies directly. These actions will lower costs for seniors and taxpayers," the official said.

"We look forward to working with the Senate to get the President’s pending nominees confirmed," they added.


NIH nominee Monica Bertagnolli

Monica M. Bertagnolli, director of the National Cancer Institute, is photographed in her office at NIH on December 13, 2022, in Bethesda, Md. (Ricky Carioti/The Washington Post via Getty Images)

Sanders previously threatened to block any of Biden's nominees last year who he said weren't prepared to "stand up and fight" against the drug industry and its pricing of drugs.

"I will strongly oppose any future nominee to a major federal health agency who is not prepared to significantly lower the price of prescription drugs in this country," he wrote at the time.

Biden announced Bertagnolli's nomination on May 15. She currently serves as the director of the National Cancer Institute, a role she has held since October 2022. She was not one of the three people Sanders recommended for the post and, at the time, he declined to say whether he would support her nomination, according to The Post's report.

No comments:

Powered by Blogger.